It is classified as operating in the Legal Services industry. This process is automatic. To date, more than 53,000 physicians across 90 countries have used Oncotype DX to optimize treatment decisions for their breast, prostate and colon cancer patients, improving outcomes and saving more than, Received acceptance to present five studies at the 16. It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients. Please dial in approximately 10 minutes prior to the start of the call. Adjustment related to new ASC 606 accounting standard: Total ASC 606 adjustment to U.S. product revenue. Find detailed stats on Genomic Health revenue on Craft. Your browser will redirect to your requested content shortly. Presented results from multiple studies in men on active surveillance at the 2019 Genitourinary Cancers Symposium demonstrating association between the Oncotype DX GPS test and adverse pathology, underscoring its value in identifying patients who will ultimately require surgery due to disease progression. Effective January 1, 2018, the company adopted new accounting guidance ASC Topic 606 ("ASC 606"), related to revenue from contracts with customers, using a modified retrospective method. U.S. product revenue was $187.0 million for the six months ended June 30, 2019, compared with $160.3 million for the same period in 2018, an increase of 16.7%. Watch how Genomic Health continues to transform cancer care around the world. [])), +((!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+[])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]-(!![]))+(!+[]+(!![])+!![]))/+((!+[]+(!![])-[]+[])+(!+[]+(!![])+!![]+!![])+(!+[]-(!![]))+(!+[]-(!![]))+(!+[]+(!![])+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])-[])+(!+[]+(!![])+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!! With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. Genomic Health's revenue is the ranked 4th among it's top 10 competitors. Multiple private insurers established reimbursement for the Oncotype DX AR-V7 Nucleus Detect test, bringing the total number of U.S. covered lives to more than 75 million, including, Additional private insurers established reimbursement for the Oncotype DX Breast Recurrence Score test in patients with 1-3 positive nodes, bringing the total number of U.S. covered lives in this breast cancer population to more than 144 million, including.

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he condensed consolidated balance sheet at December 31, 2017, has been derived from the audited consolidated financial statements at that date included in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Included in operating expenses for the six months ended June 30, 2019 were non-cash charges of $19.3 million, including $12.8 million of stock-based compensation expense and $6.5 million of depreciation and amortization expenses, compared with non-cash charges for the same period in 2018 of $16.5 million, including $10.3 million of stock-based compensation expense and $6.2 million of depreciation and amortization expenses. Revenue delivered across key product areas was as follows: Net income was $16.0 million, or $0.43 and $0.42 per share on a basic and diluted basis, respectively, for the second quarter of 2019, an improvement of $7.7 million, compared with net income of $8.3 million, or $0.23 per share on a basic and diluted basis, for the second quarter of 2018. It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients. Conference Call Details To access the live conference call today, July 29, 2019, at 8:00 a.m. Eastern Time via phone, please dial (877) 201-0168 from the United States and Canada, or +1 (647) 788-4901 internationally.

View original content to download multimedia:http://www.prnewswire.com/news-releases/genomic-health-reports-record-2018-fourth-quarter-and-year-end-financial-results-and-provides-2019-financial-guidance-300799164.html, Investors: Emily Faucette, Genomic Health, 650-569-2824, [email protected] OR Media: Victoria Steiner, Genomic Health, 415-370-5804, [email protected]. Non-GAAP operating income was $38.8 million for 2018, an improvement of $41.0 million, compared with a non-GAAP operating loss of $2.2 million for 2017.

Daten über Ihr Gerät und Ihre Internetverbindung, darunter Ihre IP-Adresse, Such- und Browsingaktivität bei Ihrer Nutzung der Websites und Apps von Verizon Media.

Sign up here to receive news alerts from Genomic Health. Cash, cash equivalents and short-term marketable securities at June 30, 2019 were $244 million, an increase of $34 million compared with $210 million at December 31, 2018.

Prepaid expenses and other current assets, Accrued expenses and other current liabilities, Total liabilities and stockholders' equity. Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API. For the three and twelve months ended December 31, 2018 compared to the same periods ended December 31, 2017, the increases in Total revenue were 22% and 18% respectively.

Included in operating expenses for the three months ended December 31, 2018 were non-cash charges of $8.6 million, including $5.3 million of stock-based compensation expense and $3.3 million of depreciation and amortization expenses, compared with non-cash charges for the same period in 2017 of $8.2 million, including $5.0 million of stock-based compensation expense and $3.2 million of depreciation and amortization expenses. Watch how Genomic Health continues to transform cancer care around the world.

In 2019, we expect this momentum to continue as we increase penetration of our Oncotype DX tests both in the U.S. and key European markets and broaden global access with national reimbursement progress. Genomic Health market cap is $2.4 b, and annual revenue was $394.11 m in FY 2018. Oncotype DX GPS tests delivered in the U.S. grew 23 percent in 2018 compared to the prior year. This process is automatic. The conference call ID is 8989205. Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer. U.S. product reported revenue was $73.5 million in the fourth quarter of 2017. Revenue growth in the fourth quarter would have been 18 percent excluding $3.5 million to reflect ASC-606 portfolio adjustments. Dies geschieht in Ihren Datenschutzeinstellungen. Genomic Health has 829 employees across 9 locations and $394.11 M in annual revenue in FY 2018. Condensed Consolidated Statements of Operations, Product revenues - Outside of the United States, Unrealized gain (loss) on investments, net, Shares used in computing basic net income (loss) per share. "2018 was a record year for Genomic Health.We delivered $394.1 million in revenue and non-GAAP net income of $39.7 million, exceeding expectations for the year.

All rights reserved.